Finally, next generation blockers of the B cell function which are being approached in autoimmune diseases, such as belimumab (B cell activating factor (BAFF) blocker) or atacicept (transmembrane activator and CALM interactor (TACI) blocker, affecting both BAFF and a proliferation-inducing ligand (APRIL)), will undoubtedly also have an effect on the B cell profile of patients, but to date there is no information on their effect on the Breg population. Here, TNFSF13B is linked to autoimmune disease.